eHealth in Antarctica: a model ready to be transferred to every-day life

Antarctic expeditions are an important testing area for technology and procedures, such as telemedicine, with analogies for space and other extreme, isolated and remote environments. Telemedicine has also implications in reducing risks and costs related to accidents and health-care in general in Antarctica. During the last 14 years, since the very beginning of Italian Antarctic activities, we have tested many different technological solutions, and set up a link between one of the largest Italian hospitals, San Camillo in Rome, and the principal Italian Antarctic Base at Terra Nova Bay. In this paper, we discuss the road we have travelled in a field with many fast technological changes, and reflect on procedures and protocols. Once we had Health, today we have eHealth.(Int J Circumpolar Health 2004; 63(4):436-442)Keywords: Antarctic, maritime satellites, telemedicin

Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials.

Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in the outpatient setting. Pharmacologic thromboprophylaxis has been shown to offer significant benefits in terms of reducing not only VTE events but also mortality, especially in acutely ill patients with COVID-19. Although the main source of evidence is derived from observational studies with several limitations, thromboprophylaxis is currently recommended for all hospitalized patients with acceptable bleeding risk by all national and international guidelines. Recently, high quality data from randomized controlled trials (RCTs) further support the role of thromboprophylaxis and provide insights into the optimal thromboprophylaxis strategy. The aim of this statement is to systematically review all the available evidence derived from RCTs regarding thromboprophylaxis strategies in patients with COVID-19 in different settings (either inpatient or outpatient) and provide evidence-based guidance to practical questions in everyday clinical practice. Clinical questions accompanied by practical recommendations are provided based on data derived from 20 RCTs that were identified and included in the present study. Overall, the main conclusions are: (i) thromboprophylaxis should be administered in all hospitalized patients with COVID-19, (ii) an optimal dose of inpatient thromboprophylaxis is dependent upon the severity of COVID-19, (iii) thromboprophylaxis should be administered on an individualized basis in post-discharge patients with COVID-19 with high thrombotic risk, and (iv) thromboprophylaxis should not be routinely administered in outpatients. Changes regarding the dominant SARS-CoV-2 variants, the wide immunization status (increasing rates of vaccination and reinfections), and the availability of antiviral therapies and monoclonal antibodies might affect the characteristics of patients with COVID-19; thus, future studies will inform us about the thrombotic risk and the optimal therapeutic strategies for these patients

Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art.

Cancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currentlyindicated for hospitalized patients with COVID-19. Also, prophylactic anticoagulation is recommended for outpatients with COVID-19 at high risk for thrombosis or disease worsening. However, whether there is an additive risk of thrombosis when a patient with cancer is infected with SARS-CoV2 remains unclear In the current review, we summarize and critically discuss the literature regarding the epidemiology of thrombotic events in patients with cancer and concomitant COVID-19, the thrombotic risk assessment, and the recommendations on thromboprophylaxis for this subgroup of patients. Current data do not support an additive thrombotic risk for patients with cancer and COVID-19. Of note, patients with cancer have less access to intensive care unit care, a setting associated with high thrombotic risk. Based on current evidence, patients with cancer and COVID-19 should be assessed with well-established risk assessment models for medically ill patients and receive thromboprophylaxis, preferentially with LMWH, according to existing recommendations. Prospective trials on well-characterized populations do not exist

Avventure Urbane. Progettare la città con gli abitanti

Nuova edizione di quello che in dieci anni è diventato uno dei testi di riferimento della progettazione urbanistica partecipata in Italia. Cinque architetti e urbanisti dialogano con un'antropologa urbana su casi di rigenerazione urbana e progettazione partecipat

Avventure Urbane. Progettare la città con gli abitanti

Nuova edizione di quello che in dieci anni è diventato uno dei testi di riferimento della progettazione urbanistica partecipata in Italia. Cinque architetti e urbanisti dialogano con un'antropologa urbana su casi di rigenerazione urbana e progettazione partecipata

Agreenment : travail et développement durable (environnement et négociation collective)

Agreenment–A Green Mentality for Collective Bargaining investigates the role of social dialogue and collective bargaining in promoting sustainable development and the Just Transition to a low-carbon economy in six countries: France, Hungary, Italy, the Netherlands, Spain and the UK

Electron Beam Welding and Vacuum Brazing Characterization for SRF Cavities

In the framework of the SPL R&D; effort at CERN, development design efforts study the joining of dissimilar metals: bulk niobium for the superconducting RF cavities and stainless steel (316LN) or titanium alloys (Ti-6Al-4V and Nb55Ti) for the cryostats. Joining techniques of electron beam welding (EBW) and vacuum brazing are particularly important for these applications. These processes have been used in the accelerator community and developed into generally accepted “best practice”. Studies were performed to update the existing knowledge, and comprehensively characterise these joints via mechanical and metallurgical investigations using modern available technologies. The developed solutions are described in detail, some currently being applied uniquely at CERN